Initial Focus on the Epidemic of Lung Cancer in China
Given the epidemic proportion of the explosion of lung cancer diagnoses and deaths in China, the CCTC’s founding clinical scientists have focused the Consortium’s initial pioneering efforts on this daunting disease entity. Leading centers of lung cancer treatment and research have therefore been recruited in multiple Chinese cities in which inaugural projects are already underway.
Recent and Ongoing Studies include:
1) A Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients with Resected Non-Small Cell Lung Cancer
2) Independent, Large Scale Validation of a Practical Molecular Assay Predictive of Survival in Resected Non-Squamous NSCLC.
See related Lancet Article entitled "A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.